title: Analysis of indoleamine 2-3 dioxygenase (IDO) and EGFR co-expression in breast cancer tissue by immunohistochemistry.
abstract: BACKGROUND
  To determine the amount of co-expression of IDO and EGFR in breast cancer patients.
  
  
  METHODS
  In order to obtain the distribution of co-expression of IDO and EGFR in breast cancer, we tested 110 breast cancer paraffin tissue blocks with immunohistochemical methods. Then we investigated the relationship between the diagnostic and pathologic characteristics (tumor size, lymph node status, histologic grade, the gene expression of ER, PR, HER2, p53, Ki67 and PCNA) with the situation of co-expression of IDO and EGFR by reviewing the medical records of 32 breast cancer patients.
  
  
  RESULTS
  Among 110 breast cancers, 32 cases demonstrated IDO and EGFR co-expression (29.1%), IDO and EGFR synchronous co-expression being found in 19.1% and asynchronous in 10.0%.
  
  
  CONCLUSIONS
  IDO and EGFR were co-expressed in breast cancer, including synchronous and asynchronous co-expression. The results suggest that considering IDO and EGFR as two indicators for breast cancer treatment or prognosis analysis provides a potential option of individual treatment for the portion of breast cancer patients with co-expression of IDO and EGFR.
authors: Department of Biological Engineering College of Pharmacy Jilin University, Changchun, China E-mail : ndz2002@126.com.
authors: Wei-Wei
authors: WW
authors: Bi
authors: Wei-Hua
authors: WH
authors: Zhang
authors: Gui-Hua
authors: GH
authors: Yin
authors: Hong
authors: H
authors: Luo
authors: Shou-Qin
authors: SQ
authors: Wang
authors: Hongran
authors: H
authors: Wang
authors: Chao
authors: C
authors: Li
authors: Wei-Qun
authors: WQ
authors: Yan
authors: De-Zhi
authors: DZ
authors: Nie
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000378:metabolism*; D066246:ErbB Receptors / Q000096:biosynthesis*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000096:biosynthesis*; D008875:Middle Aged; D016612:Paraffin Embedding; D011379:Prognosis; D014021:Tissue Preservation
chemical_list: D014408:Biomarkers, Tumor; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; C512478:EGFR protein, human; D066246:ErbB Receptors